Chemoprevention clinical trials: It is time to turn success into progress

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 8, 2007, Pages 1531-1532

  Brown, Powel H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AROMATASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; LETROZOLE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER RISK; CHEMOPROPHYLAXIS; COLON POLYP; EDITORIAL; HEAD AND NECK CANCER; HOT FLUSH; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOSIS; UTERUS CANCER; VAGINAL DRYNESS;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CHEMOPREVENTION; CLINICAL TRIALS; CLINICAL TRIALS, PHASE III; DRUG COSTS; DRUG DESIGN; DRUG INDUSTRY; FEMALE; HUMANS; NEOPLASMS; RESEARCH SUPPORT; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 34548104864     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0594     Document Type: Editorial

References (12)

1. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
2. Steombach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
3. Bertagnolli MM, Eagle CJ, Azuber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
4. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
5. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-82.
6. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
7. Cummings SR, Eckert S, Kreuger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results of the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
8. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer: 96 month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-82.
9. Vogel V, Constantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
10. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
11. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 2003;361:296-300.
12. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 2002;359:2131-9.